|
| Study year | Study design | Baseline Lp(a) | Follow-up | Treatment | Control | Clinical outcome | Patients | No. of patients |
| Lp(a) |
|
| Ram et al., 2007 [38] | Prospective study | | 3 months
12 months | SRVG | — | Significant decrease in Lp(a) levels in both groups | Women with obesity
Men with obesity | 14
11 |
|
| Williams et al., 2007 [39] | Prospective study | | 3 months
6 months
12 months | RYGB | — | Significant decrease in Lp(a) levels | Patients with obesity | 121
103
85 |
|
| Morton and Boussard, 2009 [40] | Prospective study | | 12 months | LRYGB | — | Significant decrease in Lp(a) levels | Adolescents with obesity | 32 |
|
| Woodard et al., 2010 [41] | Prospective study |
| 12 months | RYGB
LAGB | — | Unchanged | Patients with obesity | 765
73 |
|
| To et al., 2012 [42] | Retrospective study | | 6 months
12 months
24 months | LSG | — | Significant decrease in Lp(a) levels at 12 months | Patients with obesity | 52
39
5 |
|
| Berk et al., 2017 [43] | Prospective study | | 3 months | RYGB or gastric banding | Obese individuals without type 2 diabetes (dietary intervention) | Unchanged | Patients with obesity without T2DM | 26 |
|
| Gómez-Martin et al., 2017 [44] | Prospective study |
| 6 months
12 months | LRYGB
SG | Women matched for age and cardiovascular risk (diet and lifestyle modification) | Unchanged | Women with obesity | 20
20 |
|
| Lin et al., 2018 [45] | Prospective study |
| 1 month
6 months | RYGB
SG | — | Significant decrease in Lp(a) levels
Significant decrease in Lp(a) levels at 1 month | Premenopausal women | 27
35 |
|
| Carmona-Maurici et al., 2020 [46] | Prospective study |
| 6 months
12 months | LRYGB or SG | — | Significant decrease in Lp(a) levels at 12 months in both groups | Patients with obesity without plaque
Patients with obesity with plaque | 34
32 |
|
| Després et al., 2020 [47] | Prospective study | | 24 hours
5 days
6 months
12 months | Biliopancreatic diversion with duodenal switch (BPD-DS) | — | Significant increase in Lp(a) levels at 5 days
Significant decrease in Lp(a) levels at 6 months | Patients with obesity | 69 |
|
| Kruschitz et al., 2020 [48] | Clinical trial | | 1 month
6 months
12 months | Laparoscopic one anastomosis gastric bypass | — | Significant decrease in Lp(a) levels | Patients with obesity, serum 25(OH)D concentrations of <75 nmol/L | 50
43
37 |
|
| Paredes et al., 2020 [49] | Retrospective study | | 12 months | SG | — | Significant decrease in Lp(a) levels
Unchanged | Patients without metabolic syndrome
Patients without metabolic syndrome | 114
94 |
|
| Ho et al., 2021 [50] | Prospective study | | 6 months
12 months | RYGB or SG or omega loop bypass | Medical weight management | Significant increase in Lp(a) levels | Patients with obesity | 59 |
|
